Fortune smiles again on WuXi AppTec with profit surge
The drug services giant has forecast a jump in revenue for the first half and a doubling of net profit, after U.S. policy concerns abated Key Takeaways: The projected results…
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
Market talk is swirling that WuXi AppTec may be preparing to shed its cell and gene therapy business to limit potential exposure to U.S. biosecurity legislation Key Takeaways: The drug…
WuXi AppTec posts lower profits but avoids more share price pain
The pharmaceutical services giant delivered lackluster half-year earnings, with revenues and profits both falling, but investors were relieved that its U.S. business took only a minor hit Key Takeaways: U.S.…
WuXi Bio prescribes share buyback to relieve revenue pain
The pharma services provider has shocked investors with a steep downward revision of its earnings outlook, slashing its full-year revenue growth forecast to just 10% from an initial 30% and…
Viva Biotech Dispenses Bitter Pill of Slowing Growth, Asset Devaluation
The contract drug services provider lost roughly 100 million yuan in the first half of this year, as its revenue growth underperformed its peers Key Takeaways: Viva Biotech’s eked out…
Buoyed by Bumper Profits, WuXi Biologics Seeks to Bolster Global Supply Chain
Drugs services provider WuXi Biologics has issued a positive earnings alert for the first half of the year, predicting revenue would rise by up to 63% and net profit would…
WuXi AppTec Revenue Soars as Changing Government Policies Bring Headaches
The CXO giant announced it expects to post record-high revenue in the first quarter of 2022 Key takeaways: WuXi AppTec said it expects year-on-year revenue growth of 65% to 68%…
Recent Articles
Fortune smiles again on WuXi AppTec with profit surge
2359.HK
603259.SHG
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK
603259.SHG
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK
603259.SHG
RELATED ARTICLES
-
WuXi group wrestles with uncertainty over pharma tariffs
2268.HK -
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
2269.HK 2359.HK
- Huge Dental hopes Hong Kong smiles on its latest listing attempt
-
Medtide launches IPO to bulk up its weight-loss business
3880.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
Joinn Labs undermined by AI as FDA phases out animal drug testing
6127.HK 603127.SHG
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
